Data Insights

Plamotamab by Xencor for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Plamotamab is under clinical development by Xencor and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Plamotamab in Diffuse Large B-Cell Lymphoma

Data Insights

Plamotamab by Xencor for Non-Hodgkin Lymphoma: Likelihood of Approval

Plamotamab is under clinical development by Xencor and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Plamotamab in Non-Hodgkin Lymphoma

Data Insights

Vudalimab by Xencor for Non-Small Cell Lung Cancer: Likelihood of Approval

Vudalimab is under clinical development by Xencor and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Non-Small Cell Lung Cancer

Data Insights

Vudalimab by Xencor for Cervical Cancer: Likelihood of Approval

Vudalimab is under clinical development by Xencor and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Data Insights

Vudalimab by Xencor for Non-Small Cell Lung Cancer: Likelihood of Approval

Vudalimab is under clinical development by Xencor and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Data Insights

Xmab-541 by Xencor for Endometrial Cancer: Likelihood of Approval

Xmab-541 is under clinical development by Xencor and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Xmab-541 in Endometrial Cancer

Data Insights

Xmab-541 by Xencor for Uterine Cancer: Likelihood of Approval

Xmab-541 is under clinical development by Xencor and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Xmab-541 in Uterine Cancer

Data Insights

Xmab-541 by Xencor for Fallopian Tube Cancer: Likelihood of Approval

Xmab-541 is under clinical development by Xencor and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Xmab-541 in Fallopian Tube Cancer

Data Insights

Xmab-541 by Xencor for Metastatic Ovarian Cancer: Likelihood of Approval

Xmab-541 is under clinical development by Xencor and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Xmab-541 in Metastatic Ovarian Cancer

Data Insights

Xmab-541 by Xencor for Peritoneal Cancer: Likelihood of Approval

Xmab-541 is under clinical development by Xencor and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Xmab-541 in Peritoneal Cancer